Venetoclax

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Venetoclax

Examples of brand names: Venclyxto [EU/DE]

ATC code: L01XX52

Main use (for orientation): Haematological malignancies

Documented research summary

Review PMID 42841466 lists CBD/venetoclax as major. The abstract read provides no primary clinical pair evidence; do not adopt the classification as established. Missing data do not establish safety.

Uncertainties and limitations

The 28 cannabinoid names in the register define the search scope, not 28 clinically studied pairs. Missing data do not establish safety.

No complete new systematic literature search and no independent medical or pharmaceutical professional approval. Note the dosage form and the country of authorisation of the product information.

Treatment phase and tumour-lysis risk are important; do not infer a new cannabinoid contraindication.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names within the documented search scope; no newly established direct finding for the target cannabinoid–drug pair. This must not be equated with 28 clinically studied combinations.

Evidence status: Drug properties from regulatory product information; insufficient data for a direct cannabinoid–drug pair finding in the material assessed.

Mechanism / drug context: Substantial CYP3A and P-gp/BCRP dependence; its own exposure-dependent toxicity profile.

Type of supporting material: Targeted product-information review and documented individual literature screening; no newly verified direct cannabinoid–drug pair study.

Clinical interpretation: Particularly careful professional assessment needed because of venetoclax exposure sensitivity and tumour-lysis risk. Magnitude of a specific cannabinoid interaction not established; do not infer an independent CBD contraindication from the review.

Context: Treatment phase and tumour-lysis risk are important; do not infer a new cannabinoid contraindication.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [V2_LABEL_D0388]: Medicine information: properties of the active substance

Statement supported: Substantial CYP3A and P-gp/BCRP dependence; its own exposure-dependent toxicity profile. Product information: drug context, not evidence for a specific cannabinoid pair or proof of safety.

Source: VENCLEXTA (VENETOCLAX) KIT VENCLEXTA (VENETOCLAX) TABLET, FILM COATED [ABBVIE INC.] [V2_LABEL_D0388]

Source role [BMED42841466]: Secondary literature: context, not independent primary evidence

Statement supported: The review abstract gives a catalogue classification for CBD/venetoclax without verified primary pair evidence; not adopted as a clinically proven severe interaction.

Source: The Pharmacokinetic and Pharmacodynamic Drug-drug Interaction Potential of Cannabidiol. [BMED42841466]

Source role [C_PROTOCOL_D0388]: Documented search result

Statement supported: Documented title/abstract search scope for the active substance. The link displays the reproducible search query, not a study or proof that no interaction exists. Search date: 22 October 2026. Further search runs are documented in the research dataset.

Source: Reproducible literature search strategy: Venetoclax [C_PROTOCOL_D0388]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: Existing individual review, label review and literature screening read in full; targeted original pharmacokinetic/interaction passages rechecked, not all prescribing information and search results newly assessed in full text. Search findings limited to documented V5 searches. PMID 42841466: review abstract in the web search result reread; full text and underlying primary evidence not verified.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[V2_LABEL_D0388] VENCLEXTA (VENETOCLAX) KIT VENCLEXTA (VENETOCLAX) TABLET, FILM COATED [ABBVIE INC.]

Original source / bibliographic reference

Authors: AbbVie Inc.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED42841466] The Pharmacokinetic and Pharmacodynamic Drug-drug Interaction Potential of Cannabidiol.

Original source / bibliographic reference

Authors: Keller GA, Aimar JA.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.2174/0118723128411684251029100517

PMID: 42841466

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[C_PROTOCOL_D0388] Reproducible literature search strategy: Venetoclax

Original source / bibliographic reference

Authors: Europe PMC; documented search run

Year: 2026

Source type: Search strategy / screening protocol – not an individual study

Source access – 23 October 2026: Research protocol with machine-readable search results – not an individual study.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility